Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline

Jeanin E. van Hooft1, Emo E. van Halsema1, Geoffroy Vanbiervliet2, Regina G. H. Beets-Tan1, John M. DeWitt1, Fergal Donnellan1, Jean-Marc Dumonceau1, Robert G. T. Glynn-Jones1, Cesare Hassan1, Javier Jiménez-Perez1, Søren Meisner10, V. Raman Muthusamy11, Michael C. Parker12, Jean-Marc Regimbeau13, Charles Sabbagh7, Jayesh Sagar8, Pieter J. Tanis15, Jo Vandervoort16, George J. Webster17, Gianpiero Manes18, Marc A. Barthet19, Alessandro Repici20

Institutions are listed at the end of article.

Introduction

Colorectal cancer is one of the most common cancers worldwide, particularly in the economically developed world [1]. Large-bowel obstruction caused by advanced colorectal cancer occurs in 8–13% of colorectal cancer patients [2–4]. The management of this severe clinical condition remains controversial [5]. Over the last decade many articles have been published on the subject of colorectal stenting for malignant colorectal obstruction, including randomized controlled trials (RCTs) and systematic reviews. However, the definitive role of self-expandable metal stents (SEMSs) in the treatment of malignant colorectal obstruction has not yet been clarified. This evidence- and consensus-based clinical guideline has been developed by the European Society of Gastrointestinal Endoscopy (ESGE) and endorsed by the American Socie-
ty for Gastrointestinal Endoscopy (ASGE) to provide practical guidance regarding the use of SEMS in the treatment of malignant colonic obstruction.

With the exception of one trial [6], all published RCTs on colonic stenting for malignant obstruction excluded rectal cancers, which were usually defined as within 8 to 10 cm of the anal verge, and colonic cancers proximal to the splenic flexure. Rectal stenting is often avoided because of the presumed association with complications such as pain, tenesmus, incontinence, and stent migration. Proximal colonic obstruction is generally managed with primary surgery, although there are no RCTs to support this assumption. Because of the aforementioned limitations, unless indicated otherwise the recommendations in this Guideline only apply to left-sided colon cancer arising from the rectosigmoid colon, sigmoid colon, descending colon, and splenic flexure, while excluding rectal cancers and those proximal to the splenic flexure, and other causes of colonic obstruction including extracolonic obstruction.

**Methods**

The ESGE commissioned this Guideline (chairs C.H. and J.-M.D.) and appointed a guideline leader (J.v.H.) who invited the listed authors to participate in the project development. The key questions were prepared by the coordinating team (E.v.H. and J.v.H.) and then approved by the other members. The coordinating team formed task force subgroups, each with its own leader, and divided the key topics among these task forces (see Appendix e1, available online).

Each task force performed a systematic literature search to prepare evidence-based and well-balanced statements on their assigned key questions. The coordinating team independently performed systematic literature searches with the assistance of a librarian. The Medline, EMBASE and Trip databases were searched including at minimum the following key words: colon, cancer, malignancy or neoplasm, obstruction and stents. All articles studying the use of SEMS for malignant large-bowel obstruction were selected by title or abstract. After further exploration of the content, the article was then included and summarized in the literature tables of the key topics when it contained relevant data (see Appendix e2, Table e1 – e5, available online). All selected articles were graded by the level of evidence and strength of recommendation according to the GRADE system [7]. The literature searches were updated until January 2014.

Each task force proposed statements on their assigned key questions which were discussed and voted on during the plenary meeting held in February 2014, Düsseldorf, Germany. In March 2014, a draft prepared by the coordinating team was sent to all group members. After agreement on a final version, the manuscript was submitted to *Endoscopy* for publication. The journal subjected the manuscript to peer review and the manuscript was amended to take into account the reviewers’ comments. All authors agreed on the final revised manuscript. The final revised manuscript was then reviewed and approved by the Governing Board of ASGE. This Guideline was issued in 2014 and will be considered for review in 2019 or sooner if new and relevant evidence becomes available. Any updates to the Guideline in the interim will be noted on the ESGE website: http://www.esge.com/esge-guidelines.html.

**Recommendations and statements**

Evidence statements and recommendations are stated in bold italics.

**General considerations before stent placement**

| Table e1, available online |

**Prophylactic colonic stent placement is not recommended. Colonic stenting should be reserved for patients with clinical symptoms and imaging evidence of malignant large-bowel obstruction, without signs of perforation (strong recommendation, low quality evidence).**

Colonic stenting is indicated only in those patients with both obstructive symptoms and radiological or endoscopic findings suspicious of malignant large-bowel obstruction. Prophylactic stenting for patients with colonic malignancy but no evidence of symptomatic obstruction is strongly discouraged because of the potential risks associated with colonic SEMS placement. The only absolute contraindication for colonic stenting is perforation. In addition, colonic stenting is less successful in patients with peritoneal carcinomatosis and tumors close to the anal verge (<5 cm) [8 – 10].

Increasing age and American Society of Anesthesiologists (ASA) classification ≥ III do not affect stent outcome (i.e. clinical success and complications) in several observational studies [11 – 16], although these are well-known risk factors for postoperative mortality after surgical treatment of large-bowel obstruction (Table 6) [17 – 19].

A contrast-enhanced computed tomography (CT) scan is recommended as the primary diagnostic tool when malignant colonic obstruction is suspected (strong recommendation, low quality evidence).

When malignant colonic obstruction is suspected, contrast-enhanced CT is recommended because it can diagnose obstruction (sensitivity 96%, specificity 93%), define the level of the stenosis in 94% of cases, accurately identify the etiology in 81% of cases, and provide correct local and distal staging in the majority of patients [5, 20]. When CT is inconclusive about the etiology of the obstructing lesion, colonoscopy may be helpful to evaluate the exact cause of the stenosis.

**Examination of the remaining colon with colonoscopy or CT colography (CTC) is recommended in patients with potentially curable obstructing colonic cancer, preferably within 3 months after alleviation of the obstruction (strong recommendation, low quality evidence).** European studies, including those that are population-based, show that synchronous colorectal tumors occur in 3% – 4% of patients diagnosed with colorectal cancer [21 – 24]. Therefore, imaging of the remaining colon after potentially curative resection is recommended in patients with malignant colonic obstruction. Current evidence does not justify routine preoperative assessment for synchronous tumors in obstructed patients by CTC or colonoscopy through the stent. However, preoperative CTC and colonoscopy through the stent appear feasible and safe in these patients and there are presently no data to discourage their use in this population [25 – 28]. The role of positron emission tomography (PET)/CT in the diagnosis of synchronous lesions remains to be elucidated [29].
Colonic stenting should be avoided for diverticular strictures or when diverticular disease is suspected during endoscopy and/or CT scan (strong recommendation, low quality evidence). Pathological confirmation of malignancy by endoscopic biopsy and/or brush cytology is not necessary in an urgent setting, such as before stent placement. However, pathology results may help to modify further management of the stented patient (strong recommendation, low quality evidence).

When malignancy is suspected after diagnostic studies, a small number of patients will have a benign cause of obstruction. Two RCTs comparing SEMS as a bridge to surgery versus emergency surgery in patients with left-sided malignant obstruction reported benign obstructive lesions in 4.6% (3/65) [30] and 8.2% (8/98) [31] of the randomized patients. These benign colonic lesions that mimic malignancy are usually due to diverticular disease. Further evidence of the difficulty of this distinction is also reflected by a systematic review showing a 2.1% prevalence of underlying adenocarcinoma of the colon in 771 patients in whom acute diverticulitis was diagnosed via CT scan [32]. Stent placement in active diverticular inflammation is associated with a risk of perforation and should therefore be avoided [33]. Furthermore, pathological confirmation of malignancy before emergency stent placement is often not feasible and is not required prior to colonic stent placement. Endoscopic biopsy and/or brush cytology for confirmation of malignancy should be obtained during the stent placement procedure, because it may be helpful in modifying the further management of the stented patient [34–36].

Preparation of obstructed patients with an enema to clean the colon distal to the stenosis is suggested to facilitate the stent placement procedure (weak recommendation, low quality evidence). Antibiotic prophylaxis in obstructed patients undergoing stenting is not indicated because the risk of post-procedural infections is very low (strong recommendation, moderate quality evidence).

There are no studies to date that have focused on bowel preparation before stent placement in obstructed patients. Symptomatic bowel obstruction is a relative contraindication to oral bowel cleansing. An enema is advisable to facilitate the stent placement procedure by cleaning the bowel distal to the stenosis.

Antibiotic prophylaxis before stent placement in patients with malignant colonic obstruction is not indicated because the risk of fever and bacteremia after stent insertion is very low. One prospective study analyzed 64 patients with colorectal cancer who underwent a stent procedure. Four of 64 patients (6.3%) had a positive post-stenting blood culture and none of the patients developed symptoms of infection within 48 hours following stent placement. Prolonged procedure time was associated with transient bacteremia (36 vs. 16 minutes, \( P < 0.01 \)) [37]. One other retrospective series of 233 patients undergoing colonic stent placement for malignant obstruction described that blood cultures had been drawn for unspecified reasons in 30 patients within 2 weeks after stent placement, showing bacteremia/fever in 7 patients (3%), which was reported as a minor complication [15].

**Table 6 Outcome of surgery according to age and American Society of Anesthesiologists (ASA) classification.**

<table>
<thead>
<tr>
<th>First author, year</th>
<th>Study population</th>
<th>Results</th>
<th>Study design</th>
<th>Level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tekkis, 2004 [18]</td>
<td>Patients undergoing surgery for acute colorectal cancer obstruction (n = 1046)</td>
<td>Multivariate analysis of in-hospital postoperative mortality: - Age &lt; 65 years: 5.4% - Age 65–67 years: 13.1%; OR 2.97 (95% CI 1.26 – 7.08) - Age 75–84 years: 21.9%; OR 4.31 (95% CI 1.83 – 10.05) - Age ≥ 85 years: 27.0%; OR 5.87 (95% CI 2.27 – 15.14) - ASA I: 2.6% - ASA II: 7.6%; OR 3.32 (95% CI 0.73 – 15.18) - ASA III: 23.9%; OR 11.73 (95% CI 2.58 – 53.36) - ASA IV – V: 42.9%; OR 22.31 (95% CI 4.58 – 109.68)</td>
<td>Nonrandomized prospective UK multicenter study</td>
<td>High quality evidence</td>
</tr>
<tr>
<td>Biondo, 2004 [17]</td>
<td>Patients undergoing emergency surgery for acute large-bowel obstruction (n = 234) Colorectal cancer 82.1% Extracolonic cancer 4.7% Benign lesions 13.2%</td>
<td>Univariate analysis of 30-day postoperative mortality: - Age ≤ 70 years: 10.7% (14/131) - Age &gt; 70 years: 29.1% (30/103); ( P &lt; 0.001 ) - ASA I: 8.1% (9/111) - ASA II: 28.5% (35/123); ( P &lt; 0.001 ) Multivariate analysis of 30-day postoperative mortality: - Age &gt; 70 years: OR 2.05 (95% CI 0.92 – 4.60) - ASA III – IV: OR 2.86 (95% CI 1.15 – 7.11)</td>
<td>No description of study design, most likely retrospective</td>
<td>Moderate quality evidence</td>
</tr>
<tr>
<td>Tan, 2010 [19]</td>
<td>Patients who underwent operative intervention for acute obstruction from colorectal malignancy (n = 134)</td>
<td>Perioperative morbidity rate: 77.6% Perioperative mortality rate: 11.9% Multivariate analysis of worse outcome (grade III – V complications, including death): - Age &gt; 60 years: OR 4.67 (95% CI 1.78 – 12.25) - ASA III – IV: OR 8.36 (95% CI 3.58 – 19.48)</td>
<td>Retrospective analysis</td>
<td>Low quality evidence</td>
</tr>
</tbody>
</table>

CI, confidence interval; OR, odds ratio.
in pancreaticobiliary endoscopy [15]. The authors of the latter article explained the lower immediate perforation rate by the skills that therapeutic ERCP endoscopists have in traversing complex strictures, understanding fluoroscopy, and deploying stents [15].

Technical considerations of stent placement

Colonic stent placement is recommended with the combined use of endoscopy and fluoroscopy (weak recommendation, low quality evidence).

SEMS placement can be performed by using either the through-the-scope (TTS) or the over-the-guidewire (OTW) technique. The majority of SEMS are inserted through the endoscope with the use of fluoroscopic guidance. The OTW technique is performed using fluoroscopic guidance with or without tandem endoscopic monitoring. Purely radiologic stent placement is performed by advancing the stent deployment system over a stiff guidewire, and technical and clinical success rates of 83%–100% and 77%–98%, respectively, have been reported in observational studies [40–45]. Retrospective studies that compared endoscopy combined with fluoroscopic guidance versus solely radiography for stent placement show comparable success rates, although with a trend towards higher technical success when the combined technique is used [16, 46–48].

Stricture dilation either before or after stent placement is discouraged in the setting of obstructing colorectal cancer (strong recommendation, low quality evidence).

Although based on low quality evidence with small patient numbers, there are strong indications to believe that stricture dilation either just before or after colonic stent placement adversely affects the clinical outcome of stenting and particularly increases the risk of colonic perforation [8, 12, 15, 49]. Pooled analyses, mainly based on retrospective data, also show increased risk of perforation after stricture dilation [47, 50, 51].

Covered and uncovered SEMS are equally effective and safe (high quality evidence). The stent should have a body diameter ≥24 mm (strong recommendation, low quality evidence) and a length suitable to extend at least 2 cm on each side of the lesion after stent deployment (weak recommendation, low quality evidence).

The clinician should be aware of specific features of the chosen stent that may affect the patient after insertion. Two meta-analyses comparing covered and uncovered SEMS for malignant colonic obstruction found similar technical success, clinical success, and overall complication rates. Uncovered SEMS showed significantly higher tumor ingrowth rates (11.4% vs. 0.9%) but were less prone to migrate than covered SEMS (5.5% vs. 21.3%) [52, 53]. The diameter of the stent also seems to influence stent outcome. In mainly retrospective analyses, the use of small-diameter stents with a body diameter <24 mm was associated with the occurrence of complications, in particular stent migration [15, 54–56]. Stent length was not identified in observational studies as a risk factor for adverse stent outcome [8, 11, 16, 45]. It is recommended to use a stent that is long enough to bridge the stenosis and to extend at least 2 cm on each side of the lesion, taking into account the degree of shortening after stent deployment [57]. Several studies, including one RCT, have shown no difference in outcomes (efficacy and safety) based on different stent designs [8, 43, 58–61].

Surgical resection is suggested as the preferred treatment for malignant obstruction of the proximal colon in patients with potentially curable disease (weak recommendation, low quality evidence). In a palliative setting, SEMS can be an alternative to emergency surgery (weak recommendation, low quality evidence).

Retrospective series have shown that SEMS may be successfully placed in malignant strictures located in the proximal colon (i.e. proximal to the splenic flexure) [8, 16, 62–64]. However, these data show conflicting results regarding SEMS outcome compared with stent placement in the left-sided colon [8, 11, 15, 16, 45, 62, 65, 66]. Emergency resection is generally considered to be the treatment of choice for right-sided obstructing colon cancer. In this setting, primary ileocolonic anastomosis or ileostomy can be performed depending on the surgical risk of the patient [5, 67, 68].

SEMS placement is a valid alternative to surgery for the palliation of malignant extracolonic obstruction (weak recommendation, low quality evidence). The technical and clinical success rates of stenting for extracolonic malignancies are inferior to those reported in stenting of primary colonic cancer (low quality evidence).

Large-bowel obstruction caused by extracolonic malignancies is a different entity within colonic stenting and has been studied mainly retrospectively. Technical and clinical success rates of stenting extracolonic malignancies have been reported to range from 67% to 96% and from 20% to 96%, respectively [65, 69–75], and are considered inferior to those reported in stenting of primary colonic cancer [8, 55, 70, 74]. One retrospective comparison of SEMS for extracolonic versus primary colonic malignancy showed an increased complication rate in the extracolonic malignancy group (33% vs. 9%, P = 0.046), although this finding was not statistically significant in the multivariate analysis [74]. However, several larger series did not identify obstruction by extrinsic compression as a risk factor for complications [8, 11, 15, 70]. It is generally advisable to attempt palliative stenting of extracolonic malignancies in order to avoid surgery in these patients who have a relatively short survival (median survival 30–141 days) [69, 70, 72, 73].

There is insufficient evidence to discourage colonic stenting based on the length of the stenosis (weak recommendation, low quality evidence) or the degree of obstruction (strong recommendation, low quality evidence).

Few studies investigated the “stentability” of long obstructed segments [58, 76, 77]. However, in two retrospective studies that included a total of 240 patients, a better outcome was observed when SEMS were inserted in short obstructed segments [55, 78]. One identified statistically significantly more technical failures (odds ratio [OR] 5.33) and clinical failures (OR 2.40) in stenoses >4 cm [55].

The outcomes of SEMS placement for complete obstruction compared with subtotal obstruction are reported inconsistently in the literature. One comparative prospective study that specifically focused on this topic found similar technical and clinical success rates between both groups [79]. This was confirmed by more recently published large retrospective series [8, 55]. However, in two observational studies significantly more complications were observed in the complete occlusion group [35% and 38% vs. 20% and 22%] [13, 15]. Furthermore, multivariate analysis in one prospective multicenter study, which reported an 11% overall perforation rate, identified complete obstruction as a risk factor for perforation (OR 6.88) [80].

Clinical indication: SEMS placement as a bridge to elective surgery (Table e3, available online)

Colonic SEMS placement as a bridge to elective surgery is not recommended as a standard treatment of symptomatic left-sided malignant colonic obstruction (strong recommendation, high quality evidence). For patients with potentially curable left-sided obstructing colonic cancer, stent placement may be considered as an alternative to emergency surgery in those who have an increased risk of postoperative mortality, i.e. ASA ≥III and/or age >70 years (weak recommendation, low quality evidence).

Eight systematic reviews with meta-analysis have been published in the last decade that compared preoperative stenting with emergency resection for acute malignant left-sided colonic obstruction [81–88]. Three of the seven RCTs published to date on this subject [30,31,89–93] were prematurely closed, including two because of adverse outcomes in the stent group [30,31] and one because of a high incidence of anastomotic leakage in the primary surgery group [92].

The most recent systematic review and meta-analysis evaluated the efficacy and safety of colonic stenting as a bridge to surgery (n = 195) compared with emergency surgery (n = 187) and considered only RCTs for inclusion (Table 7) [81]. All seven RCTs that focused on the postoperative outcome of SEMS and emergency surgery were included in this meta-analysis. The mean technical success rate of colonic stent placement was 76.9% (range 46.7%–100%) [81]. There was no statistically significant difference in the postoperative mortality comparing SEMS as bridge to surgery (10.7%) and emergency surgery (12.4%) [81]. The meta-analysis showed the SEMS group had lower overall morbidity (33.1% vs. 53.9%, P < 0.001), a higher successful primary anastomosis rate (67.2% vs. 55.1%, P < 0.01), and lower permanent stoma rate (9% vs. 27.4%, P < 0.01) [81].

No clear conclusions may be drawn about differences in costs between the two procedures. In the two RCTs that compared costs between SEMS as bridge to surgery and emergency surgery, stenting seems to be the more costly strategy [91,92]. Cost-effectiveness depends on the rate of stent complications, in particular perforation, and a greater benefit of stenting is expected in high risk surgical patients [94].

From the above data, some advantages of SEMS as a bridge to surgery can be extracted. However, this has to be balanced with the oncological outcomes in patients with a curable colonic cancer. Potential concerns have been raised about impaired oncological outcome after SEMS placement in the patient with potentially curable colonic cancer, particularly following stent perforation. Long-term oncological outcome comparing SEMS as a bridge to elective surgery versus acute resection was analyzed by three RCTs (Table e8) [90,92,95]. Although the study groups were small, with 15 to 26 patients in the stent arms, all three report higher disease recurrence rates in the SEMS group. This did not translate into a worse overall survival in any of these RCTs, but this may be related to short follow-up and small sample sizes [90,92,95]. These results are further supported by a larger comparative prospective cohort study showing significantly more local disease recurrences in the stent group compared with the primary surgery group in patients ≥75 years of age [96]. However, no difference in survival was seen between the two groups. One retrospective analysis reported a significantly lower 5-year overall survival and significantly increased cancer-related mortality in the SEMS as bridge-to-surgery group [97]. The use of SEMS and the occurrence of tumor perforation were identified to correlate with worse overall survival. Follow-up data of the Stent-in-2 trial also showed a significantly higher overall recurrence rate in the SEMS group compared with the surgery group (42% vs. 25%), which was even higher in the subgroup of patients who experienced stent-related perforation (83%) [95].

The oncological risks of SEMS should be balanced against the operative risks of emergency surgery. Because there is no reduction in postoperative mortality and stenting seems to impact on the oncological safety, the use of SEMS as a bridge to elective surgery is not recommended as a standard treatment for potentially curable patients with left-sided malignant colonic obstruction. However, placement of SEMS may be considered an alternative option in patients at high surgical risk. The known risk factors associated with adverse outcomes following elective as well as emergency surgery in colorectal cancer are increasing age and an ASA score ≥III [3,17–19,98,99]. Therefore, the use of SEMS as a bridge to elective surgery may be considered an acceptable alternative treatment option in patients older than 70 years and/or with an ASA score ≥III [100].

A time interval to operation of 5–10 days is suggested when SEMS is used as a bridge to elective surgery in patients with potentially curable left-sided colon cancer (weak recommendation, low quality evidence).

There are limited data to determine an optimal time interval to operation following stent placement as a bridge to surgery. Theoretically, a longer interval (≥1 week) will allow for better recovery and more nearly optimal nutritional status, but this may increase the risk of stent-related complications and may compromise surgery by more local tumor infiltration and fibrosis. Therefore, we suggest a 5–to 10-day interval between SEMS and elective resection. Data from the abstract of one RCT (n = 49) published in Chinese, which compared laparoscopic resection 3 and 10 days after stent placement, reported a significantly higher primary anastomosis rate and a lower conversion rate to open procedure when surgery was deferred until 10 days after stenting [101]. A retrospective analysis revealed an anastomotic leakage rate of 20% (3/15) for an interval of 1 to 9 days and 0% (0/28) when surgery was delayed for 10 days or longer (P = 0.037) [102]. A published abstract comparing resection within 7 days (n = 26) and after 7 days (n = 30) of stent placement, found no differences in the postoperative morbidity and mortality [103]. In the literature, a median time interval to surgery of 10 days is a common practice considering the patient’s clinical condition, potential risk of stent-related complications, and impact on oncological outcomes [84].

Clinical indication: palliative SEMS placement (Table e4, available online)

SEMS placement is the preferred treatment for palliation of malignant colonic obstruction (strong recommendation, high quality evidence).

Two meta-analyses, including randomized and nonrandomized comparative studies, have compared SEMS (n = 195 and n = 404) and surgery (n = 215 and n = 433) for palliation of malignant colonic obstruction (Table 9) [104,105]. The technical success of stent placement in the studies included ranged from 88% to 100% [6,106], while the initial clinical relief of obstruction was significantly higher after palliative surgery (100%) compared with stent placement (93%; P < 0.001) [104,105].
Both meta-analyses showed a lower 30-day mortality rate for SEMS, but it was significant only in the larger meta-analysis (4% vs. 11%, SEMS vs. surgery, respectively) [105]. Placement of a SEMS was significantly associated with a shorter hospitalization (10 vs. 19 days) and a lower intensive care unit (ICU) admission rate (0.8% vs. 18.0%) [104,105], while permitting a shorter time to initiation of chemotherapy (16 vs. 33 days) [105,107]. Surgical stoma formation was significantly lower after palliative SEMS compared with emergency surgery (13% vs. 54%) [105].

The larger meta-analysis showed no significant difference in overall morbidity between the stent group (34%) and the surgery group (38%) [105]. Short-term complications did occur more often in the palliative surgery group, while late complications were more frequent in the SEMS group. Stent-related complications mainly included colonic perforation (10%), stent migration (9%) and re-obstruction (18%) [105].

The aforementioned results are supported by other recently published literature, including one RCT that was not included in the meta-analyses [11,55,108–114]. There are insufficient data regarding the outcome of stent placement in patients with peritoneal carcinomatosis (Table e1, available online). One large retrospective study showed a significantly lower technical success rate in patients with carcinomatosis compared with patients without carcinomatosis (83% vs. 93%) [8]. Another series, that focused on the outcomes of secondary SEMS insertion after initial stent failure, reported a significantly decreased stent patency in the setting of carcinomatosis (83% vs. 93%).

Despite the lower probability of success, SEMS placement may be an alternative to surgical decompression in the setting of peritoneal carcinomatosis. However, there is a lack of evidence to underpin a definite recommendation on this topic.

**Patients who have undergone palliative stenting can be safely treated with chemotherapy without antiangiogenic agents (strong recommendation, low quality evidence).** Given the high risk of colonic perforation, it is not recommended to use SEMS as palliative decompression if a patient is being treated or considered for treatment with antiangiogenic therapy (e.g. bevacizumab) (strong recommendation, low quality evidence).

It has been speculated that chemotherapy during stenting might induce stent-related complications, in particular perforation. It has been speculated that chemotherapy during stenting might induce stent-related complications, in particular perforation. Given the high risk of colonic perforation, it is not recommended to use SEMS as palliative decompression if a patient is being treated or considered for treatment with antiangiogenic therapy (e.g. bevacizumab) (strong recommendation, low quality evidence).

Both meta-analyses showed a lower 30-day mortality rate for SEMS, but it was significant only in the larger meta-analysis (4% vs. 11%, SEMS vs. surgery, respectively) [105]. Placement of a SEMS was significantly associated with a shorter hospitalization (10 vs. 19 days) and a lower intensive care unit (ICU) admission rate (0.8% vs. 18.0%) [104,105], while permitting a shorter time to initiation of chemotherapy (16 vs. 33 days) [105,107]. Surgical stoma formation was significantly lower after palliative SEMS compared with emergency surgery (13% vs. 54%) [105].

The larger meta-analysis showed no significant difference in overall morbidity between the stent group (34%) and the surgery group (38%) [105]. Short-term complications did occur more often in the palliative surgery group, while late complications were more frequent in the SEMS group. Stent-related complications mainly included colonic perforation (10%), stent migration (9%) and re-obstruction (18%) [105]. The aforementioned results are supported by other recently published literature, including one RCT that was not included in the meta-analyses [11,55,108–114]. There are insufficient data regarding the outcome of stent placement in patients with peritoneal carcinomatosis (Table e1, available online). One large retrospective study showed a significantly lower technical success rate in patients with carcinomatosis compared with patients without carcinomatosis (83% vs. 93%) [8]. Another series, that focused on the outcomes of secondary SEMS insertion after initial stent failure, reported a significantly decreased stent patency in the setting of carcinomatosis (83% vs. 93%).

Despite the lower probability of success, SEMS placement may be an alternative to surgical decompression in the setting of peritoneal carcinomatosis. However, there is a lack of evidence to underpin a definite recommendation on this topic.

**Patients who have undergone palliative stenting can be safely treated with chemotherapy without antiangiogenic agents (strong recommendation, low quality evidence).** Given the high risk of colonic perforation, it is not recommended to use SEMS as palliative decompression if a patient is being treated or considered for treatment with antiangiogenic therapy (e.g. bevacizumab) (strong recommendation, low quality evidence).

It has been speculated that chemotherapy during stenting might induce stent-related complications, in particular perforation.
<table>
<thead>
<tr>
<th>First author, year</th>
<th>Study population</th>
<th>Results</th>
<th>Study design</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sloothaak, 2013 [95]¹</td>
<td>Patients with acute left-sided colonic obstruction, proven malignancy, and curable disease</td>
<td>Preoperative SEMS (n = 26) Emergency surgery (n = 32)</td>
<td>Follow-up data of RCT [31] Moderate quality evidence</td>
</tr>
<tr>
<td>Tung, 2013 [90]</td>
<td>Patients with obstructing left-sided colon cancer</td>
<td>Preoperative SEMS (n = 24) Emergency surgery (n = 24)</td>
<td>Follow-up data of RCT [93] Moderate quality evidence</td>
</tr>
<tr>
<td>Alcantara, 2011 [92]</td>
<td>Patients with complete intestinal obstruction due to tumor in the left colon</td>
<td>SEMS as bridge to surgery (n = 15) Intraoperative colonic lavage with primary anastomosis (n = 13)</td>
<td>RCT Moderate quality evidence</td>
</tr>
<tr>
<td>Gorissen, 2013 [96]</td>
<td>Patients with obstructing left-sided colonic cancer</td>
<td>Preoperative SEMS (n = 62) Emergency surgery (n = 43)</td>
<td>Prospective cohort study Moderate quality evidence</td>
</tr>
</tbody>
</table>
Several retrospective series reported an increased risk of stent perforation (17%–50%) in patients treated with bevacizumab, an angiogenesis inhibitor [15, 55, 116]. A meta-analysis, searching for risk factors of stent perforation in a heterogeneous population, found a significantly increased perforation rate in patients receiving bevacizumab (12.5%) compared with patients who received no concomitant therapy during colorectal stenting (9.0%), while chemotherapy without bevacizumab was not associated with an increased risk of stent perforation (7.0%) [51]. Despite the lack of evidence, an increased perforation risk can reasonably be extrapolated to the newer antiangiogenic agents, aflibercept and regorafenib, because of the similar therapeutic mechanism. Therefore, SEMS placement is strongly discouraged for patients who are being treated or considered for further treatment with antiangiogenic drugs.

Low quality published evidence showed contradictory results regarding the outcome of stenting during chemotherapy [8, 11, 117]. Nevertheless, no clear increase in adverse events has been observed with colonic stenting. Palliative chemotherapy in patients with a colonic stent is associated with prolonged survival [76, 118], and might therefore result in more patients being exposed to the risk of late stent complications. Suspicion of an association between chemotherapy and the occurrence of stent migration due to tumor shrinkage is prompted by several retrospective series [43, 119, 120].

Long-term stent complications are not automatically an argument in favor of palliative surgery. The lower short-term mortality and the early start of chemotherapy because of SEMS should not be disregarded.

**Adverse events related to colonic stenting**

(© Table e5, available online)

When stent obstruction or migration occurs in the palliative setting, endoscopic re-intervention by stent-in-stent placement or SEMS replacement is suggested (weak recommendation, low quality evidence). Surgery should always be considered in patients with stent-related perforation (strong recommendation, low quality evidence). Colonic SEMS placement in patients with malignant large-bowel obstruction is associated with potential adverse events. However, the 30-day stent-related mortality rate is less than 4% [11, 12, 105]. Median stent patency in the palliative setting ranges widely between 55 days and 343 days [58, 59]. One systematic review published in 2007 found a median stent patency of 106 days (range 68–288 days) in the palliative stent population [121]. Around 80% (range 53–90%) of patients maintain stent patency until death or end of follow-up [48, 55, 109, 113, 117, 122]. In the bridge-to-surgery setting, stent patency is maintained until surgery in the large majority of patients. Adverse events related to colonic stent placement are usually divided into early (<30 days) and late (>30 days). The main early complications are perforation (range 0%–12.8%), stent failure after technically successful stent deployment (range 0%–11.7%), stent migration (range 0%–4.9%), re-obstruction (range 0%–4.9%), pain (range 0%–7.4%), and bleeding (range 0%–3.7%) [8, 12, 31, 109]. Late adverse events related to SEMS mainly include re-obstruction (range 4.0%–22.9%) and stent migration (range 1.0%–12.5%), and more rarely perforation (range 0%–4.0%) [8, 11, 105, 109, 113, 117, 122], although one RCT reported late perforations in 4 out of 10 stent patients [123]. Other SEMS complications reported less frequently in the literature are tenesmus (up to 22%, related to rectal SEMS), incontinence, and fistula [16, 109, 112, 122].

Stent-related perforation may result from different causes which can be classified as proposed by Baron et al.: (i) guidewire or catheter malpositioning; (ii) dilation of the stricture before or after stent placement; (iii) stent-induced perforation (tumor and

---

Table 8 (Continuation)

<table>
<thead>
<tr>
<th>First author, year</th>
<th>Study population</th>
<th>Results</th>
<th>Study design</th>
<th>Level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sabbagh, 2013 [97]</td>
<td>Patients operated on for left-sided malignant colonic obstruction with curative intent Preoperative SEMS (n = 48) Emergency surgery (n = 39)</td>
<td>Mean follow-up (P = 0.21): – SEMS as bridge to surgery: 28 months – Emergency surgery: 32 months 5-year overall survival rate (P &lt; 0.001): – SEMS as bridge to surgery: 25% – Emergency surgery: 62% 5-year cancer-specific mortality (P = 0.02): – SEMS as bridge to surgery: 48% – Emergency surgery: 21% 5-year disease-free survival (P = 0.24): – SEMS as bridge to surgery: 22% – Emergency surgery: 32% Overall recurrence rate (P = 0.18): – SEMS as bridge to surgery: 33% – Emergency surgery: 20% Mean time to recurrence (P = 0.92): – SEMS as bridge to surgery: 16 months – Emergency surgery: 23 months In multivariate analysis SEMS (HR 2.42, 95% CI 1.13–5.18) and tumor perforation (HR 5.96, 95% CI 1.70–20.95) were associated with overall survival</td>
<td>Retrospective intention-to-treat analysis Low quality evidence</td>
<td></td>
</tr>
</tbody>
</table>

CI, confidence interval; HR, hazard ratio; IQR, interquartile range; RCT, randomized controlled trial.

1 Published in abstract form.
<table>
<thead>
<tr>
<th>First author, year</th>
<th>Study population</th>
<th>Results</th>
<th>Study type</th>
</tr>
</thead>
</table>
| Liang, 2014 [104] | Patients with malignant colorectal obstruction caused by advanced malignancy | Major stent-related complications:  
- Short-term (< 30 days) perforation rate: 3.7%  
- Long-term (≥ 30 days) perforation rate: 7.6%  
- Overall stent migration rate: 8.9%  
- Re-obstruction: not analyzed.  
Successful relief of obstruction:  
- Palliative SEMS: 94%  
- Surgery: 100%  
Short-term (< 30 days) complication rate (P = 0.22):  
- Palliative SEMS: 26.2% (51/195)  
- Surgery: 34.5% (74/215)  
- OR 0.83 (95% CI 0.39 – 1.79)  
Long-term (≥ 30 days) complication rate (P = 0.03):  
- Palliative SEMS: 16.1% (25/155)  
- Surgery: 8.1% (14/173)  
- OR 2.34 (95% CI 1.07 – 5.14)  
Overall complication rate (P = 0.56):  
- Palliative SEMS: 43.9% (68/155)  
- Surgery: 45.1% (78/173)  
- OR 1.27 (95% CI 0.58 – 2.77)  
Overall mortality rate (P = 0.22):  
- Palliative SEMS: 7.1% (12/169)  
- Surgery: 11.6% (22/189)  
- OR 0.60 (95% CI 0.27 – 1.34)  
SEMS required significantly shorter hospitalization: weighted mean difference – 6.07 days (95% CL – 8.40, – 3.74); P < 0.01 | Systematic reviews and meta-analysis of comparative studies  
High quality evidence |
| Zhao, 2013 [105] | Patients with malignant colorectal obstruction that was unresectable | Mean length of hospital stay (P < 0.001):  
- Palliative SEMS: 9.6 days  
- Surgery: 18.8 days,  
ICU admission rate (P = 0.001):  
- Palliative SEMS: 0.8% (1/119)  
- Surgery: 18.0% (22/122)  
- RR 0.09 (95% CI 0.02 – 0.38); I² = 0%  
Mean interval to chemotherapy:  
- Palliative SEMS: 15.5 days  
- Surgery: 33.4 days  
Clinical relief of obstruction (P < 0.001):  
- Palliative SEMS: 93.1% (375/403)  
- Surgery: 99.8% (433/434)  
- RR 0.96 (95% CI 0.93 – 0.98); I² = 3%  
In-hospital mortality rate (P = 0.01):  
- Palliative SEMS: 4.2% (14/334)  
- Surgery: 10.5% (37/354)  
- RR 0.46 (95% CI 0.25 – 0.85); I² = 0%  
Overall complication rate (P = 0.60):  
- Palliative SEMS: 34.0% (137/403)  
- Surgery: 38.1% (172/452)  
- RR 0.91 (95% CI 0.64 – 1.29); I² = 66%  
Early complication rate (P = 0.03):  
- Palliative SEMS: 13.7% (41/300)  
- Surgery: 33.7% (110/326)  
- RR 0.45 (95% CI 0.22 – 0.92); I² = 66%  
Late complication rate (P < 0.001):  
- Palliative SEMS: 32.3% (60/186)  
- Surgery: 12.7% (27/213)  
- RR 2.33 (95% CI 1.55 – 3.50); I² = 0%  
Stent complications:  
- Perforation rate: 10.1%  
- Stent migration: 9.2%  
- Stent obstruction: 18.3%  
Overall survival time (P = n.s.):  
- Palliative SEMS: 7.6 months  
- Surgery: 7.9 months  
Stoma formation rate (P < 0.001):  
- Palliative SEMS: 12.7% (38/299)  
- Surgery: 54.0% (170/315)  
- RR 0.26 (95% CI 0.18 – 0.37); I² = 18% | Systematic review and meta-analysis of comparative studies  
High quality evidence |

CI, confidence interval; CI, confidence limits; ICU, intensive care unit; n.s., not significant; OR, odds ratio; RCT, randomized controlled trial; RR, risk ratio.
nontumor local perforation); and (iv) proximal colonic distension because of inadequate colonic decompression or excessive air insufflation [57]. The final outcome of stent perforation has been inconsistently reported in the literature, although a perforation-related mortality rate of 50% is observed in a number of prospective and retrospective studies [11,55,120,123]. Furthermore, there are strong indications that perforation compromises the oncological outcome in patients with colorectal cancer [95,97,124]. Concurrent bevacizumab therapy, intraprocedural and post-stenting stricture dilation, and diverticular strictures were identified by several studies as risk factors for stent-related perforation [12,15,33,47,51,55].

Stent migration can occur at any time following colonic stenting. Factors that have been identified to correlate with the occurrence of migration are use of covered SEMS and of small-diameter (<24 mm) stents [15,52,54,55], and there is some evidence that chemotherapy may also be associated with stent migration by the mechanism of tumor shrinkage [43,119,120]. Tumor ingrowth/overgrowth is the main cause of stent re-obstruction and usually occurs during the long-term course of stent therapy. The use of uncovered SEMS is a risk factor for tumor ingrowth [52]. One retrospective series focusing on predictive factors of stent occlusion found that <70% stent expansion within the first 48 hours is also predictive for the occurrence of re-obstruction [125]. Both migration and re-obstruction can be managed endoscopically. Stent replacement and stent reopening by a stent-in-stent approach is feasible [26,428,268], but the use of uncovered SEMS is a risk factor for tumor ingrowth [52].

ESGE guidelines represent a consensus of best practice based on the available evidence at the time of preparation. They may not apply in all situations and should be interpreted in the light of specific clinical situations and resource availability. Further controlled clinical studies may be needed to clarify aspects of these statements, and revision may be necessary as new data appear. Clinical consideration may justify a course of action at variance to these recommendations. ESGE guidelines are intended to be an educational device to provide information that may assist endoscopists in providing care to patients. They are not rules and should not be construed as establishing a legal standard of care or as encouraging, advocating, requiring, or discouraging any particular treatment.

**Competing interests:** J. E. van Hooft: consultancy work for Cook Medical, Boston Scientific, Abbott and Covidien; J. M. Dewitt: consultant for Boston Scientific, Olympus America, and Apollo Endosurgery without grant nor honoraria. S. Meisner: consultancy work for Coloplast Denmark, Olympus Denmark, Olympus Europe, Boston Scientific. Dr. V. Muthusami: consultant for Boston Scientific. Dr. A. Repici received a consulting fee and speech fee from Boston Scientific and research grants from Fujifilm, Covidien GI solution and Merit Medical. G. Webster: Advisory Board for Cook Medical and Boston Scientific. All other authors disclosed no financial relationships relevant to this publication.

**Institutions**

1. Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands
2. Centre Hospitalier Universitaire de l’Arche, Pôle digestif, Nice, France
3. Department of Radiology, Maastricht University Medical Center, The Netherlands
4. Department of Gastroenterology and Hepatology, Indiana University Medical Center, Indianapolis, Indiana, United States
5. UBC Division of Gastroenterology, Vancouver General Hospital, Vancouver, Canada
6. Gedyt Endoscopy Center, Buenos Aires, Argentina
7. Mount Vernon Cancer Centre, Northwood, Middlesex, UK
8. Digestive Endoscopy Unit, Catholic University, Rome, Italy
9. Endoscopy Unit, Gastroenterology Department, Complejo Hospitalario de Navarra, Pamplona, Spain
10. Endoscopy Unit, Digestive Disease Center, Bispebjerg University Hospital, Copenhagen, Denmark
11. Division of Gastroenterology and Hepatology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States
13. Department of Digestive and Oncological Surgery, University Hospital of Amiens, France
14. Department of Colorectal Surgery, Royal Surrey County Hospital, Guildford, UK
15. Department of Surgery, Academic Medical Center, Amsterdam, The Netherlands
16. Department of Gastroenterology, Onze-Lieve-Vrouwekliniek, Aalst, Belgium
17. Department of Gastroenterology, University College Hospital, London, UK
18. Department of Gastroenterology and Endoscopy, Guido Salvini Hospital, Garbagnate Milanese/Rho, Milan, Italy
19. Department of Gastroenterology, Hôpital Nord, Aix Marseille Université, Marseille, France
20. Digestive Endoscopy Unit, Istituto Clinico Humanitas, Milan, Italy

**References**

van Hooft Jeanin E et al. SEMSs for obstructing colonic and extracolonic cancer: ESGE Clinical Guideline... Endoscopy 2014; 46: 990–1002


Iversen LH. Aspects of survival from colorectal cancer in Denmark. Dan Med J 2012; 59: B44828


Appendix e1 and e2

online content viewable at: www.thieme-connect.de